UCSF Brain Tumor Center Clinical Trials
Our clinical trials evaluate a broad range of innovative therapies for both adults and children with brain tumors.
-
Recruiting
- Pediatrics
- On Hold
Conditions
Glioma
Glioblastoma
The FRONTIER Study is a prospective, interventional, single-arm, multi-center study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
Conditions
Glioblastoma
Glioma
In this phase II study, researchers will study whether treatment with atezolizumab provides a therapeutic benefit for patients with recurrent glioblastoma and a low mutational burden.
Conditions
Glioma
Glioblastoma
This single-center Phase I/Ib study in recurrent glioblastoma (GBM) aims to establish a recommended phase 2 dose of the mTOR inhibitor RMC-552 in GBM participants as well as to evaluate safety and antitumor effect of this drug.
Conditions
Glioblastoma
Glioma
This is randomized multi-site phase II clinical trial that aims to assess whether a ketogenic diet improves overall survival in newly diagnosed glioblastoma patients who receive standard of care treatment when compared to the standard anti-cancer diet.
Conditions
Glioma
Astrocytoma
Glioblastoma
Pleomorphic xanthoastrocytoma (grades II-III)
The phase I trial will evaluate the safety and efficacy of nivolumab and ipilimumab before and after surgery in treating children and young adults with recurrent or progressive high grade glioma.
Conditions
Glioma
Glioblastoma
Astrocytoma
Oligodendroglioma
This is an international, open-label phase II clinical trial for recurrent patients who have a glioma harboring a BRAF abnormality.
Conditions
Glioma
Glioblastoma
This phase II/III clinical trial is a response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed and recurrent GBM.
Conditions
Glioma
Glioblastoma
This is a first-in-human phase I study to assess the safety and feasibility of using an IV infusion of E-SYNC T cells to treat patients with EGFRvIII-mutated glioblastoma (GBM).
Conditions
Glioma
Astrocytoma
Glioblastoma
This is a multicenter, open-label study of DB107-RRV (formerly Toca 511) and DB107-FC (formerly Toca FC) when administered following surgical resection in patients with newly diagnosed high grade glioma.
Conditions
Diffuse Midline Glioma
Glioma
Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Glioblastoma
Brainstem Glioma
Ependymoma
This phase I clinical trial will evaluate ONC206 alone or in combination with radiation therapy in treating pediatric patients with newly diagnosed or recurrent DMGs, or other recurrent primary malignant brain tumors.
Conditions
Choroid Plexus Tumors
Pituitary Tumor
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
Pineal Region Tumors
Glioma
Astrocytoma
Medulloblastoma
Oligodendroglioma
Glioblastoma
Ependymoma
Primary Objectives:
Conditions
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
Glioma
Glioblastoma
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
Natural killer (NK) cells are immune cells that recognize and get rid of abnormal cells in the body, including tumor cells and cells infected by viruses. NK cells have been shown to kill different types of cancer, including brain tumors in laboratory settings.